Gross Margin % is calculated as gross profit divided by its revenue. Illumina's Gross Profit for the
three
months ended in Mar. 2022 was $815 Mil. Illumina's Revenue for the
three
months ended in Mar. 2022 was $1,223 Mil. Therefore, Illumina's Gross Margin % for the quarter that ended in Mar. 2022 was 66.64%.
The historical rank and industry rank for Illumina's Gross Margin % or its related term are showing as below:
ILMN'
s Gross Margin % Range Over the Past 10 Years
Min: 64.16 Med: 69.24 Max: 69.77
Current: 68.81
During the past 13 years, the highestGross Margin % of Illumina was 69.77%. The lowest was 64.16%. And the median was 69.24%.
ILMN's Gross Margin % is ranked better than 76.55% of 226
companies
in the Medical Diagnostics & Research industry
Industry Median: 50.09
vs ILMN: 68.81
Illumina had a gross margin of 66.64% for the quarter that ended in Mar. 2022 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Illumina was 0.30% per year.
Illumina Gross Margin % Historical Data
The historical data trend for Illumina's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Illumina Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Gross Margin %
66.35
69.01
69.63
68.01
69.69
Illumina Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Gross Margin %
69.90
71.23
69.49
68.14
66.64
Competitive Comparison
For the Diagnostics & Research subindustry, Illumina's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Illumina Gross Margin % Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Illumina's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Illumina (NAS:ILMN) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Illumina had a gross margin of 66.64% for the quarter that ended in Mar. 2022 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Illumina Gross Margin % Related Terms
Thank you for viewing the detailed overview of Illumina's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
2.74(1.14%) Volume: 969,986 10:08PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:ILMN has been successfully added to your 
